Effectiveness of Statin-Gemfibrozil Combination Therapy in Patients with Mixed Hyperlipidemia: Experience of a Community Lipid Clinic and Safety Review from the Literature

Preventive Cardiology

Volumn 6, Issue 4, 2003, Pages 189-194

  Shammas, Nicolas W ^a   Kapalis, Matthew J ^b   Deckert, Judi ^b   Harris, Melodee ^b   Dippel, Eric J ^b   Labroo, Ajay ^b   McKinney, Dawn ^b  

^a Cardiovascular Medicine Davenport   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; FLUINDOSTATIN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HYPERLIPIDEMIA; LIPOPROTEIN BLOOD LEVEL; MALE; MYALGIA; MYOPATHY; MYOSITIS; REVIEW; RHABDOMYOLYSIS; SIDE EFFECT; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0242662536     PISSN: 1520037X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1520-037X.2003.02200.x     Document Type: Review

References (42)

1. Smith SC Jr, Blair SN, Bonow RO, et al. AHA/ACC guidelines for preventing heart attack and death with atherosclerotic cardiovascular disease: 2001 update. J Am Coll Cardiol. 2001;38:1581-1583.
2. Athyros VG, Papageorgiou AA, Hatzikonstandinou HA, et al. Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia. Am J Cardiol. 1997;80:608-613.
3. Murdock DK, Murdock AK, Murdock RW, et al. Long-term safety and efficacy of combination gemfibrozil and HMG-CoA reductase inhibitors for the treatment of mixed lipid disorders. Am Heart J. 1999;138:151-155.
4. Wallace CS, Mueller BA. Lovastatin-induced rhabdomyolysis in the absence of concomitant drugs. Ann Pharmacother. 1992;26(2):190-192.
5. Sylvain-Moore H, Worden JP Jr. Lovastatin-associated rhabdomyolysis. Heart Lung. 1991;20(5 pt 1):464-466.
6. Chu PH, Chen WJ, Chiang CW, et al. Rhabdomyolysis, acute renal failure and hepatopathy induced by lovastatin monotherapy. Jpn Heart J. 1997;38(4):541-545.
7. Manoukian AA, Bhagavan NV, Hayashi T, et al. Rhabdomyolysis secondary to lovastatin therapy. Clin Chem. 1990;36(12):2145-2147.
8. Deslypere JP, Vermeulen A. Rhabdomyolysis and simvastatin. Ann Intern Med. 1991;114(4):342.
9. Berland Y, Vacher Coponat H, Durand C, et al. Rhabdomyolysis with simvastatin use. Nephron. 1991; 57(3):365-366.
10. Bizzaro N, Bagolin E, Milani L, et al. Massive rhabdomyolysis and simvastatin. Clin Chem. 1992;38(8 pt 1):1504.
11. Ucar M, Mjorndal T, Dhalqvist R. HMG-CoA reductase inhibitors and myotoxicity. Drug Saf. 2000;22(6):441-457.
12. Rodriguez ML, Mora C, Navarro JF. Cerivastatin-induced rhabdomyolysis. Ann Intern Med. 2000;132(7):598.
13. Kogan AD, Orenstein S. Lovastatin-induced acute rhabdomyolysis. Postgrad Med J. 1990;66:294-296.
14. Gorriz JL, Sancho A, Lopez-Martin JM, et al. Rhabdomyolysis and acute renal failure associated with gemfibrozil therapy. Nephron. 1996;74(2):437-438.
15. Magarian GJ, Lucas LM, Colley C. Gemfibrozil-induced myopathy. Arch Intern Med. 1991;151(9):1873-1874.
16. Duell PB, Connor WE, Illingworth DR. Rhabdomyolysis after taking atorvastatin with gemfibrizol. Am J Cardiol. 1998; 81(3):368-369.
17. Pogson GW, Kindred LH, Carper BG. Rhabdomyolysis and renal failure associated with cerivastatin-gemfibrizol combination therapy. Am J Cardiol. 1999;83(7):1146.
18. Bermingham RP, Whitsitt TB, Smart ML, et al. Rhabdomyolysis in a patient receiving the combination of cerivastatin and gemfibrizol. Am J Health Syst Pharm. 2000;57(5):461-464.
19. Alexandridis G, Pappas GA, Elisaf MS. Rhabdomyolysis due to combination therapy with cerivastatin and gemfibrizol. Am J Med. 2000;109 (3):261-262.
20. Ozdemir O, Boran M, Gokce V, et al. A case with severe rhabdomyolysis and renal failure associated with cerivastatin-gemfibrizol combination therapy-a case report. Angiology. 2000;51(8):695-697.
21. Pierce LR, Wysowski DK, Gross TP. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination. JAMA. 1990;264(1):71-75.
22. Goldstein MR. Myopathy and rhabdomyolysis with lovastatin taken with gemfibrozil. JAMA. 1990;264(23):2991-2992.
23. Abdul-Ghaffar N, El-Sonbaty MR. Pancreatitis and rhabdomyolysis associated with lovastatin-gemfibrozil therapy. J Clin Gastroenterol. 1995;21(4):340-341.
24. Glueck CJ, Oakes N, Speirs J, et al. Gemfibrozil-lovastatin therapy for primary hyperlipoproteinemias. Am J Cardiol. 1992;70:1-9.
25. Marais GE, Larson KK. Rhabdomyolysis and acute renal failure induced by combination lovastatin and Gemfibrozil therapy. Ann Intern Med. 1990;112(3):228-230.
26. Van Puijenbroek EP, Du Buf-Vereijken PW, Spooren PF, et al. Possible increased risk of rhabdomyolysis during concomitant use of simvastatin and gemfibrozil. J Intern Med. 1996; 240(6):403-404.
27. Tal A, Raieshhawari M, Isley W. Rhabdomyolysis associated with simvastatin-gemfibrozil therapy. South Med J. 1997; 90(5):546-547.
28. Illingworth DR, Bacon S. Influence of lovastatin plus gemfibrozil on plasma lipids and lipoproteins in patients with heterozygous familial hypercholesterolemia. Circulation. 1989; 79:590-596.
29. Napoli C, Lepore S, Chiariello P, et al. Long term treatment with pravastatin alone and in combination with gemfibrozil in familial type IIB hyperlipoproteinemia or combined hyperlipidemia. J Cardiovasc Pharmacol Ther. 1997;2(1):17-26.
30. Pasternak RC, Brown LE, Stone PH, et al., for the Harvard Atherosclerosis Reversibility Project (HARP) Study Group. Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels. A randomized, placebo-controlled trial. Ann Intern Med. 1996;125:529-540.
31. Wiklund O, Bergman M, Bondjers G, et al. Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia. Am J Med. 1993;94(1):13-20.
32. Rosenson RS, Frauenheim WA. Safety of combined pravastatin-gemfibrozil therapy. Am J Cardiol. 1994;74:499-500.
33. Spence JD, Munoz CE, Hendricks L, et al. Pharmacokinetics of the combination of fluvastatin and gemfibrozil. Am J Cardiol. 1995;76:80A-83A.
34. Tobert JA. Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation [letter]. N Engl J Med. 1988; 318(1):47-48.
35. Iliadis EA, Rosenson RS. Long-term safety of pravastatin-gemfibrozil therapy in mixed hyperlipidemia. Clin Cardiol. 1999;22:25-28.
36. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
37. Pasternak RC, Smith SC Jr, Bairey-Merz CN, et al. ACC/AHA/NHLBI Clinical Advisory on the use and safety of statins. Circulation. 2002;106:1024-1028.
38. Statins are not all alike: study reveals no increased risk of musculoskletal effects. From data presented at the XIV International Symposium on Drugs Affecting lipid Metabolism (DALM), MediView Express Report. September 9-12, 2001.
39. Igel M, Sudhop T, Bergmann K. Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A-reductase inhibitors (statins). Eur J Clin Pharmacol. 2001;57:357-364.
40. Kwak B, Mulhaupt F, Myit S, et al. Statins as a newly recognized type of immunomodulator. Nat Med. 2000;6:1399-1402.
41. Fukumoto Y, Libby P, Rabkin E, et al. Statins alter smooth muscle cell accumulation and collagen content in established atheroma of Watanabe heritable hyperlipidemic rabbits. Circulation. 2001;103(7):993-999.
42. Shiomi M, Ito T, Hirouchi Y, et al. Fibromuscular cap composition is important for the stability of established atherosclerotic plaques in mature WHHL rabbits treated with statins. Atherosclerosis. 2001;157:75-84.